

Form PTO-1449 Modified		Docket No. JANS-0079/ 1734-PCT-USA	Application No. 10/540,456
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Frans E. Janssens, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 22, 2005	Group 1624
		Confirmation No. 1422	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
/B.C./	1	5,310,743	05/10/94	Schilling et al.	514	311
/B.C./	2	5,541,195	07/30/96	Schilling et al.	514	311
/B.C./	3	5,646,144	07/08/97	Schilling et al.	514	241

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
/B.C./	4	01/30348 A1	05/03/01	WO	X	
/B.C./	5	02/062784 A1	08/15/02	WO	X	
/B.C./	6	02/32867 A1	04/25/02	WO	X	
/B.C./	7	97/16440 A1	05/09/97	WO	X	
** /B.C./	8	0 532 456 A1	03/17/93	EP		X

EXAMINER	/Brenda Coleman/	DATE CONSIDERED	02/29/2008
-----------------	------------------	------------------------	------------

Form PTO-1449 Modified		Docket No. JANS-0079/ 1734-PCT-USA	Application No. 10/540,456
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Frans E. Janssens, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 22, 2005	Group 1624
		Confirmation No. 1422	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/B.C./	9	Aguiar, M. S. et al., "Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test," <i>Physiol. Behav.</i> , <u>1996</u> , 60, 1183-1186
/B.C./	10	Antiemetic Subcommittee, "Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC)," <i>Annals Oncol.</i> , <u>1998</u> , 9(8), 811-819
/B.C./	11	Arvanitis, L., "Efficacy and Tolerability of Four Novel Compounds in Schizophrenia: Results of the Metatrial Project," <i>ACNP Meeting</i> , December 10, <u>2001</u> , Abstract 144, p. 178
/B.C./	12	Ballard, T. M. et al., "Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK ₁ receptor antagonist," <i>Eur. J. Pharmacol.</i> , <u>Feb. 2001</u> , 412(3), 255-264
/B.C./	13	Bertand, C. et al., "Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergic airway disease," <i>Trends Pharmacol. Sci.</i> , <u>1996</u> , 17(7), 255-259
/B.C./	14	Brodin, E. et al., "Effects of sequential removal of rats from a group cage, and of individual housing of rats, on substance P, cholecystokinin and somatostatin levels in the periaqueductal grey and limbic regions," <i>Neuropeptides</i> , <u>Apr. 1994</u> , 26(4), 253-260
/B.C./	15	Campos et al., "Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone," <i>J. Clin. Oncol.</i> , <u>2001</u> , 19, 1759-1767
/B.C./	16	Cocquyt, V. et al., "Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis," <i>Eur. J. Cancer</i> , <u>May 2001</u> , 37(7), 835-842
/B.C./	17	Culman, J. et al., "Central tachykinins: mediators of defence reaction and stress reactions," <i>Can. J. Physiol. Pharmacol.</i> , <u>1995</u> , 73(7), 885-891

EXAMINER	/Brenda Coleman/	DATE CONSIDERED	02/29/2008
-----------------	------------------	------------------------	------------

Form PTO-1449 Modified		Docket No. JANS-0079/ 1734-PCT-USA	Application No. 10/540,456
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Frans E. Janssens, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 22, 2005	Group 1624
		Confirmation No. 1422	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/B.C./	18	DeMulder et al., "Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study," <i>Annals of Internal Medicine</i> , 1990, 113, 834-840
/B.C./	19	Elliott, P.J., "Place aversion induced by the substance P analogue, dimethyl-C7, is not state dependent: implication of substance P in aversion," <i>Exp. Brain Res.</i> 1988, 73(2), 354-356
/B.C./	20	Giardina, G. et al., "Recent Advances in neurokinin-3 receptor antagonists," <i>Exp. Opin. Ther. Patents</i> , 2000, 10(6), 939-960
/B.C./	21	Hesketh et al., "Proposal for classifying the acute emetogenicity of cancer chemotherapy," <i>J. Clin. Oncol.</i> , 1997, 15(1), 103-109
/B.C./	22	Hesketh et al., "Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis," <i>J. Clin. Oncol.</i> , 1999, 17, 338-343
/B.C./	23	Kramer, M. S. et al., "Distinct mechanism for antidepressant activity by blockade of central substance P receptors," <i>Science</i> , 1998, 281(5383), 1640-1645
/B.C./	24	Krase et al., "Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats," <i>Behav. Brain. Res.</i> , 1994, 63, 81-88
/B.C./	25	Kris et al., "Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin," <i>J. Clin. Oncol.</i> , 1985, 3, 1379-1384
/B.C./	26	Lejeune, F. et al., "Selective, non-peptidergic Neurokinin ₁ (NIK ₁) Antagonists Enhance the Activity of Frontocortical Dopaminergic and Adrenergic, but not Serotonergic, Pathways in Rats," <i>Abstracts Soc. Neurosci.</i> , Abstract No. 477.1, November 2001, p. 1253
/B.C./	27	Longmore, J. et al., "Neurokinin Receptors," <i>DN&P</i> , 1995, 8(1), 5-23
/B.C./	28	Lundberg, J. M., "Tachykinins, sensory nerves, and asthma--an overview," <i>Can. J. Physiol. Pharmacol.</i> , 1995, 73(7), 908-914

EXAMINER	/Brenda Coleman/	DATE CONSIDERED	02/29/2008
-----------------	------------------	------------------------	------------

Form PTO-1449 Modified		Docket No. JANS-0079/ 1734-PCT-USA	Application No. 10/540,456
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Frans E. Janssens, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 22, 2005	Group 1624
		Confirmation No. 1422	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/B.C./	29	Maggi, C. A. et al., "The dual nature of the tachykinin NK ₁ receptor," <i>Trends Pharmacol. Sci.</i> , <u>1997</u> , 18(10), 351-355
/B.C./	30	Maggi, C. A., "The mammalian tachykinin receptors," <i>Gen. Pharmacol.</i> , <u>1995</u> , 26(5), 911-944
/B.C./	31	Mattson, R. J. et al., "An Improved Method for Reductive Alkylation of Amines Using Titanium (IV) Isopropoxide and Sodium Cyanoborohydride," <i>J. Org. Chem.</i> , <u>1990</u> , 55, 2552-2554
/B.C./	32	Megens, A. A. et al., "Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist," <i>J. Pharmacol. Exp. Ther.</i> , <u>2002</u> , 302(2), 696-709
/B.C./	33	Navari, R. M. et al., "Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group," <i>N. Engl. J. Med.</i> , <u>1999</u> , 340(3), 190-195
/B.C./	34	Naylor, R. J. et al., "Emesis and anti-emesis," <i>Cancer Surv.</i> , <u>1994</u> , 21, 117-135
/B.C./	35	Okano, S. et al., "Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo," <i>J. Pharmacol. Exp. Ther.</i> , <u>2001</u> , 298(2), 559-564
/B.C./	36	Piedimonte, G. et al., "A new NK ₁ receptor antagonist (CP-99,994) prevents the increase in tracheal vascular permeability produced by hypertonic saline," <i>J. Pharmacol. Exp. Ther.</i> , <u>1993</u> , 266, 270-273
/B.C./	37	Regoli, D. et al., "Receptors and antagonists for substance P and related peptides," <i>Pharmacol. Rev.</i> , <u>1994</u> , 46(4), 551-599
/B.C./	38	Roila, F. "Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination," <i>Oncology</i> , <u>1993</u> , 50(3), 163-167
/B.C./	39	Rudd, J. A. et al., "Effects of 5-HT ₃ receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret," <i>Neuropharmacology</i> , <u>1994</u> , 33(12), 1607-1608

EXAMINER	/Brenda Coleman/	DATE CONSIDERED	02/29/2008
-----------------	------------------	------------------------	------------

Form PTO-1449 Modified		Docket No. JANS-0079/ 1734-PCT-USA	Application No. 10/540,456
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Frans E. Janssens, et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date June 22, 2005	Group 1624
		Confirmation No. 1422	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/B.C./	40	Rudd, J. A. et al., "The action of the NK ₁ tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret," <i>Br. J. Pharmacol.</i> , 1994, 119(5), 931-936
/B.C./	41	Rupniak, N. M. et al., "Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists," <i>Trends Pharmacol. Sci.</i> , 1999, 20(12), 485-490
/B.C./	42	Sam, T. S. et al., "Action of glucocorticoids to antagonise cisplatin-induced acute and delayed emesis in the ferret," <i>Eur. J. Pharmacol.</i> , 2001, 417(3), 231-237
/B.C./	43	Shirayama, Y. et al., "Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat," <i>Brain Res.</i> , 1996, 739(1-2), 70-78
/B.C./	44	Stella, V. J. et al., "Prodrugs. Do they have advantages in clinical practice?" <i>Drugs</i> , 1985, 29, 455-473
/B.C./	45	Stella, V. J. et al., "Prodrugs", <i>Drug Delivery Systems</i> , 1985, pp. 112-176
/B.C./	46	Tattersall, F. D. et al., "Tachykinin NK ₁ receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets," <i>Neuropharmacol.</i> , 1996, 35(8), 1121-1129
/B.C./	47	Tattersall, F. D. et al., "The novel NK ₁ receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets," <i>Neuropharmacology</i> , 2000, 39(4), 652-663
/B.C./	48	Teixeira, R. M. et al., "Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice," <i>Eur. J. Pharmacol.</i> , 1996, 311, 7-14
/B.C./	49	Tonini, M. et al., "Tachykinin-dependent and -independent components of peristalsis in the guinea pig isolated distal colon," <i>Gastroenterol.</i> , 2001, 120, 938-945
/B.C./	50	Watson, J. W. et al., "The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK ₁ receptor," <i>Br. J. Pharmacol.</i> , 1995, 115, 84-94
/B.C./	51	Wilson, C. O. et al., (Ed.), <i>Textbook of Organic Medicinal and Pharmaceutical Chemistry</i> , Seventh Edition, 1977, J. B. Lippincott Company, pp. 70-75

EXAMINER	/Brenda Coleman/	DATE CONSIDERED	02/29/2008
-----------------	------------------	------------------------	------------